Telix Pharmaceuticals Limited (TLX)
Nasdaq: TLX · Pharmaceutical Preparations · North Melbourne, AU · filing with the SEC since 2024
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts in thousands. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Report filed | Feb 20, 2026 | Feb 24, 2025 | · |
| Revenue | 803,794 | 516,551 | 332,978 |
| Cost of revenue | 377,356 | 180,388 | 123,445 |
| Gross profit | 426,438 | 336,163 | 209,533 |
| Research and development | 171,249 | 127,930 | 85,315 |
| Sales and marketing | 96,766 | 55,953 | 33,464 |
| General and administrative | 95,789 | 85,318 | 49,668 |
| Operating income | 29,776 | 55,177 | 11,008 |
| Finance costs | 40,868 | 24,442 | 9,085 |
| Finance income | 5,826 | 7,180 | 671 |
| Other gains and losses | 11,735 | 4,885 | -23,827 |
| Income before income taxes | -5,266 | 37,915 | 2,594 |
| Income tax expense | 1,859 | 4,230 | -1,614 |
| Net income | -7,125 | 33,685 | 4,208 |
| Net income to shareholders | -7,125 | 33,685 | 4,208 |
| Earnings per share, basic | -0.0211 | 0.1017 | 0.0132 |
| Earnings per share, diluted | -0.0211 | 0.0976 | 0.013 |
| Weighted average shares, basic | 337,880 | 331,226 | 319,181 |
| Weighted average shares, diluted | 337,880 | 345,188 | 323,710 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
ifrs-full:RevenueCost of revenue what it cost to make or buy what it sold
ifrs-full:CostOfSalesGross profit revenue less the cost of what it sold
ifrs-full:GrossProfitResearch and development spent on inventing what it sells next
ifrs-full:ResearchAndDevelopmentExpenseSales and marketing the cost of finding and serving customers
ifrs-full:SalesAndMarketingExpenseGeneral and administrative the cost of running the company itself
ifrs-full:GeneralAndAdministrativeExpenseOperating income profit from running the business, before interest and tax
ifrs-full:ProfitLossFromOperatingActivitiesFinance costs what its borrowing cost
ifrs-full:FinanceCostsFinance income what its cash and investments earned
ifrs-full:FinanceIncomeOther gains and losses gains and costs outside the business
ifrs-full:OtherGainsLossesIncome before income taxes profit before tax
ifrs-full:ProfitLossBeforeTaxIncome tax expense tax charged on the period's profit
ifrs-full:IncomeTaxExpenseContinuingOperationsNet income the whole group's profit, minority holders' share included
ifrs-full:ProfitLossNet income to shareholders the profit or loss that belongs to the company's shareholders
ifrs-full:ProfitLossAttributableToOwnersOfParentEarnings per share, basic net income per share outstanding
ifrs-full:BasicEarningsLossPerShareEarnings per share, diluted net income per share, counting every share that could be issued
ifrs-full:DilutedEarningsLossPerShareWeighted average shares, basic the average count of shares outstanding
ifrs-full:WeightedAverageSharesWeighted average shares, diluted the average count with every share that could be issued
ifrs-full:AdjustedWeightedAverageShares